Hematology

FDA approves first treatment for newly diagnosed light chain (AL) amyloidosis

The U.S. Food and Drug Administration has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. Daratumumab and hyaluronidase-fihj is the only FDA-approved treatment for this disorder and is subcutaneous formulation of daratumumab. It...